Phase 2 N=24 Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer
Breast Cancer
Primary: Change in Ki-67 in Breast Tissue of High-Risk Women
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=36 Vitamin D and Residual Beta-Cell Function in Type 1 Diabetes
Type 1 Diabetes
Primary: Residual Beta-cell Function (RBCF) — 1.78; 2.27; 1.56; 1.76 ng/ml — p=<0.001
Phase 2 N=105 A Study of the Safety, Tolerability and Efficacy of Treatment With AP1189 in Early RA Patients With Active Joint Disease
Rheumatoid Arthritis
Primary: Change in Clinical Disease Activity Index (CDAI) — 18; 17; 12 Participants
Phase 2 N=273 First-line Metastatic Pancreatic Cancer : FOLFIRINOX +/- LV5FU2 in Maintenance Versus Firgem
Metastatic Pancreatic Cancer
Primary: Percentage of Patients Alive and Without Radiological and/or Clinical Progression 6 Months After the Randomization. — 41; 39; 30 Participants
Phase 2 N=117 Aflibercept +/- LV5FU2 in First Line of Non-resectalbe Metastatic Colorectal Cancers
Colorectal Neoplasms
Primary: The Primary Objective Was the Percentage of Patients Alive and Without Progression 6 Months After the Randomization. — 30; 30; 26; 26 Participants
N/A N=37 Menthol Flavored E-cigarette Use During a Simulated Ban of Menthol Cigarettes
Tobacco Use Disorder
Primary: Number of Cigarettes Smoked Per Day — 2.2; 1.8; 6.0; 7.1 model estimated cigarettes per day
N/A N=75 Behavioral Economic Treatment to Enhance Rural (BETTER) Living
Alcohol Use, Unspecified
Primary: Feasibility of the Intervention - Screening — 17; 21; 19; 18 Participants
Phase 2 N=64 Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer
Advanced Melanoma · Triple-Negative Breast Cancer
Primary: The Primary Efficacy Endpoint Was ORR, Defined as the Proportion of Subjects Demonstrating CR or PR Based on RECIST v1.1 Criteria. — 1; 1; 0; 5 Participants
Phase 2 N=63 Alvelestat (MPH966) for the Treatment of ALpha-1 ANTitrypsin Deficiency
Alpha-1 Antitrypsin Deficiency (AATD) · Pi*ZZ, Pi*SZ, Pi*Null, Another Rare Phenotype/Genotype Known to be Associated With Either Low or Functionally Impaired AAT Including F or I Mutations · Emphysema or COPD
Primary: Within-individual % Change in Plasma Desmosine/Isodesmosine — 10.0619; 8.5627 % change
Phase 2 N=127 FIrst Line Treatment of Metastatic Pancreatic Cancer: Sequential Nab-paclitaxel + Gemcitabine/FOLFIRI.3 VS Nab-paclitaxel + Gemcitabine
Metastatic Pancreatic Cancer
Primary: Percentage of Patients Alive and Without Radiological and/or Clinical Progression 6 Months After the Randomization — 28; 14 Participants
N/A N=35 Enhancement of Emmetropization in Highly Hyperopic Infants
Hyperopia
Primary: Central Cycloplegic Refractive Error With Retinoscopy — 1.6; 1.2; 2.8 Diopters
Phase 3 N=50 The Effect of N115 on Coughing in IPF Patients
Idiopathic Pulmonary Fibrosis
Primary: Percent Change in Coughing Episodes Per Day From Baseline to Day 21. — -73.2; -16.1 % change in coughing episodes — p=0.0001
N/A N=11 Evaluation of The Postprandial Impact of Automated Priming Bolus for Full Closed Loop Insulin Delivery
Type 1 Diabetes
Primary: Difference in Daytime Percent Time-in-range — 67.4; 65.1 percentage of CGM values — p=0.4291
N/A N=718 The Prevent Anal Cancer Palpation Study
Anal Cancer
Primary: Concordance Between Self-examination and Clinician Examination — 234; 247 Participants
Phase 2 N=6 A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer
Breast Cancer · Breast Cancer Stage IV · HER2-negative Breast Cancer
Primary: Dose Limiting Treatment/DLT Evaluable Population